These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2960 related items for PubMed ID: 21180382

  • 1. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 2. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [Abstract] [Full Text] [Related]

  • 3. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
    Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
    [Abstract] [Full Text] [Related]

  • 4. [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].
    Rougier P, Mitry E.
    Gastroenterol Clin Biol; 2009 Jun; 33(8-9):672-80. PubMed ID: 19717258
    [Abstract] [Full Text] [Related]

  • 5. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J.
    J Clin Oncol; 2007 Oct 20; 25(30):4779-86. PubMed ID: 17947725
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
    Clin Ther; 2011 Apr 20; 33(4):482-97. PubMed ID: 21635994
    [Abstract] [Full Text] [Related]

  • 7. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S.
    Lancet Oncol; 2014 Sep 20; 15(10):1065-75. PubMed ID: 25088940
    [Abstract] [Full Text] [Related]

  • 8. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
    Prescrire Int; 2005 Dec 20; 14(80):215-7. PubMed ID: 16400742
    [Abstract] [Full Text] [Related]

  • 9. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S, Bracco-Nolin CH, Legat-Fagnoni C, Chaigneau L, Stein U, Huchet B, Pivot X, Woronoff-Lemsi MC.
    Eur J Health Econ; 2006 Jun 20; 7(2):107-13. PubMed ID: 16474968
    [Abstract] [Full Text] [Related]

  • 10. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Ajima H, Ogata H, Fujita K, Miwa K, Sunakawa Y, Mizuno K, Ishida H, Yamashita K, Nakayama H, Kawara K, Takahashi H, Sasaki Y.
    Jpn J Clin Oncol; 2010 Jul 20; 40(7):634-8. PubMed ID: 20587616
    [Abstract] [Full Text] [Related]

  • 11. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.
    J Clin Oncol; 2012 Oct 01; 30(28):3499-506. PubMed ID: 22949147
    [Abstract] [Full Text] [Related]

  • 12. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.
    Clin Colorectal Cancer; 2013 Dec 01; 12(4):239-47. PubMed ID: 24188685
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM.
    Cancer; 2005 Nov 01; 104(9):1871-84. PubMed ID: 16177989
    [Abstract] [Full Text] [Related]

  • 14. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A.
    J Clin Oncol; 2005 Jan 20; 23(3):502-9. PubMed ID: 15659495
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
    Prescrire Int; 2011 Feb 20; 20(113):46-9. PubMed ID: 21488594
    [Abstract] [Full Text] [Related]

  • 16. Is there a third-line therapy for metastatic colorectal cancer?
    Grothey A.
    Semin Oncol; 2006 Dec 20; 33(6 Suppl 11):S36-8. PubMed ID: 17178284
    [Abstract] [Full Text] [Related]

  • 17. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.
    N Engl J Med; 2014 Oct 23; 371(17):1609-18. PubMed ID: 25337750
    [Abstract] [Full Text] [Related]

  • 18. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.
    Lancet Oncol; 2010 Sep 23; 11(9):853-60. PubMed ID: 20708966
    [Abstract] [Full Text] [Related]

  • 19. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.
    J Clin Oncol; 2012 Oct 10; 30(29):3596-603. PubMed ID: 22965965
    [Abstract] [Full Text] [Related]

  • 20. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
    Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Gao S, Klingman D.
    Curr Med Res Opin; 2012 Feb 10; 28(2):221-9. PubMed ID: 22171947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 148.